D&D Pharmatech is showing a weak trend, falling more than 8% in the afternoon session on the 23rd.

In the KOSDAQ market today, D&D Pharmatech is trading at 98,600 won, down 8,900 won (8.28%) from the previous trading day during the afternoon session. Daily trading volume has exceeded 2 million shares, with relatively active trading continuing.

Recently, D&D Pharmatech showed a steep upward trend, driven by expectations for new drug development and growing recognition of its technological capabilities. The stock price, which was at the 80,800 won level on the 16th, rose to as high as 114,400 won during trading on the 19th, recording a sharp increase in a short period of time.

However, as profit-taking pressures have grown following the recent gains, investor sentiment appears to have somewhat contracted. Some market analyses suggest that a process of absorbing sell orders is underway, particularly among stocks that have recently surged. On the order book today, sell volumes exceeded buy volumes, sustaining downward pressure on the stock price, and at one point during the session, the price dropped to the 98,000 won range, widening the decline.

The securities industry believes that, given the characteristics of biotech stocks, price volatility can significantly increase depending on clinical trial progress, research and development achievements, and technology transfer outcomes. In particular, following the recent sharp rise, the range of fluctuations may widen due to changes in supply and demand, requiring investors to take a cautious approach.

[※ This article was written with the assistance of AI based on publicly available data and market information. The content included in this article is for reference only in making investment decisions and does not constitute a recommendation to buy or sell any specific stock or guarantee any returns. The stock market can fluctuate due to various variables, so investment decisions should be made based on the investor's own judgment and responsibility. As there may be some misinterpretation or errors in information during the AI analysis process, please be sure to verify disclosure materials and company announcements before making any final investment decisions.]